Biomarkers in translational research of Alzheimer's Disease

Neuropharmacology

Volumn 59, Issue 4-5, 2010, Pages 310-322

  Tarawneh, Rawan ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Antecedent biomarkers; Biomarkers; Imaging; Plaques; Tau

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BIOLOGICAL MARKER; NEURONAL CALCIUM SENSOR; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN;

ALZHEIMER DISEASE; BRAIN SIZE; BRAIN TISSUE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; HUMAN; INTERSTITIAL FLUID; MILD COGNITIVE IMPAIRMENT; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOXEL BASED MORPHOMETRY;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; TRANSLATIONAL RESEARCH;

EID: 77955919746     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.04.006     Document Type: Review

References (134)

1. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
2. Arai H., Nakagawa T., Kosaka Y. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer's Res. 1997, 3:211-213.
3. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C.M., Miura M., Machida N., Lee V.M., Trojanowski J.Q., Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 1997, 236:262-264.
4. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., Matsui T., Morikawa Y., Horikawa E., Kohno H., Sasaki H., Imahori K. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 2000, 166:201-203.
5. Bailey P. Biological markers in Alzheimer's disease. Can. J. Neurol. Sci. 2007, 34(Suppl. 1):S72-S76.
6. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
7. Barnes J., Lewis E.B., Scahill R.I., Bartlett J.W., Frost C., Schott J.M., Rossor M.N., Fox N.C. Automated measurement of hippocampal atrophy using fluid-registered serial MRI in AD and controls. J. Comput. Assist. Tomogr. 2007, 31:581-587.
8. Baron J.C., Chetelat G., Desgranges B., Perchey G., Landeau B., de la Sayette V., Eustache F. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001, 14:298-309.
9. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666-669.
10. Benzing W.C., Ikonomovic M.D., Brady D.R., Mufson E.J., Armstrong D.M. Evidence that transmitter-containing dystrophic neurites precede paired helical filament and Alz-50 formation within senile plaques in the amygdala of nondemented elderly and patients with Alzheimer's disease. J. Comp. Neurol. 1993, 334:176-191.
11. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
12. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 2001, 24:87-97.
13. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
14. Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med. 2004, 256:224-234.
15. Bobinski M., de Leon M.J., Wegiel J., Desanti S., Convit A., Saint Louis L.A., Rusinek H., Wisniewski H.M. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
16. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Koeppe R.A., Meltzer C.C., Constantine G., Davis J.G., Mathis C.A., Dekosky S.T., Moore R.Y. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:315-319.
17. Bouwman F.H., Schoonenboom S.N., van der Flier W.M., van Elk E.J., Kok A., Barkhof F., Blankenstein M.A., Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging 2007, 28:1070-1074.
18. Braak H., Braak E. Neuropil threads occur in dendrites of tangle-bearing nerve cells. Neuropathol. Appl. Neurobiol. 1988, 14:39-44.
19. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
20. Brys M., Pirraglia E., Rich K., Rolstad S., Mosconi L., Switalski R., Glodzik-Sobanska L., De Santi S., Zinkowski R., Mehta P., Pratico D., Saint Louis L.A., Wallin A., Blennow K., de Leon M.J. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 2009, 30:682-690.
21. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25:7709-7717.
22. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
23. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H., Davies P., Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002, 59:627-629.
24. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttila T., Schapiro M.B., Rapoport S.I., Moller H.J., Davies P., Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 2002, 59:1267-1272.
25. Chetelat G., Landeau B., Eustache F., Mezenge F., Viader F., de la Sayette V., Desgranges B., Baron J.C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005, 27:934-946.
26. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 2009, 50:1887-1894.
27. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
28. Committee on Health Effects Associated with Exposures During the Gulf War.Institute of Medicine Gulf War and Health: Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines 2000, National Academy Press, Washington D.C.
29. Convit A., de Asis J., de Leon M.J., Tarshish C.Y., De Santi S., Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol. Aging 2000, 21:19-26.
30. de Leon M.J., Golomb J., George A.E., Convit A., Tarshish C.Y., McRae T., De Santi S., Smith G., Ferris S.H., Noz M., et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am. J. Neuroradiol. 1993, 14:897-906.
31. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10966-10971.
32. de Leon M.J., Segal S., Tarshish C.Y., DeSanti S., Zinkowski R., Mehta P.D., Convit A., Caraos C., Rusinek H., Tsui W., Saint Louis L.A., DeBernardis J., Kerkman D., Qadri F., Gary A., Lesbre P., Wisniewski T., Poirier J., Davies P. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci. Lett. 2002, 333:183-186.
33. de Leon M.J., Mosconi L., Blennow K., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Tsui W., Saint Louis L.A., Sobanska L., Brys M., Li Y., Rich K., Rinne J., Rusinek H. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N.Y. Acad. Sci. 2007, 1097:114-145.
34. DeKosky S.T. Taking the next steps in the diagnosis of Alzheimer's disease: the use of biomarkers. CNS Spectr. 2008, 13:7-10.
35. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
36. 18F]FDG PET study. Neurology 2007, 68:501-508.
37. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Langstrom B., Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
38. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
39. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
40. Fagan A.M., Mintun M.A., Aldea P., Shah A.R., Roe C.M., Mach R.H., Marcus D., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 2009, 1:371-380.
41. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5856-5861.
42. Fiala J.C., Spacek J., Harris K.M. Dendritic spine pathology: cause or consequence of neurological disorders?. Brain. Res. Brain Res. Rev. 2002, 39:29-54.
43. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
44. Gironell A., Garcia-Sanchez C., Estevez-Gonzalez A., Boltes A., Kulisevsky J. Usefulness of p300 in subjective memory complaints: a prospective study. J. Clin. Neurophysiol. 2005, 22:279-284.
45. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996, 16:4491-4500.
46. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
47. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
48. Griffin W.S., Sheng J.G., McKenzie J.E., Royston M.C., Gentleman S.M., Brumback R.A., Cork L.C., Del Bigio M.R., Roberts G.W., Mrak R.E. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiol. Aging 1998, 19:401-405.
49. Grunwald M., Busse F., Hensel A., Kruggel F., Riedel-Heller S., Wolf H., Arendt T., Gertz H.J. Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia. J. Clin. Neurophysiol. 2001, 18:178-184.
50. Gusnard D.A., Raichle M.E. Searching for a baseline: functional imaging and the resting human brain. Nat. Rev. Neurosci. 2001, 2:685-694.
51. Haass C., Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993, 75:1039-1042.
52. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61:95-102.
53. Hampel H., Burger K., Teipel S.J., Bokde A.L., Zetterberg H., Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008, 4:38-48.
54. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
55. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am. J. Psychiatry 2005, 162:676-682.
56. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 2001, 297:187-190.
57. Hu Y.Y., He S.S., Wang X., Duan Q.H., Grundke-Iqbal I., Iqbal K., Wang J. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 2002, 160:1269-1278.
58. Hu Y., Hosseini A., Kauwe J.S.K., Gross J., Cairns N.J., Goate A.M., Fagan A.M., Townsend R.R., Holtzman D.M. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin. Appl. 2007, 1373-1384.
59. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
60. Jack C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., Kokmen E. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998, 51:993-999.
61. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
62. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
63. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., L Whitewell J., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 2008, 27:685-691.
64. Jackson C.E., Snyder P.J. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimers Dement. 2008, 4:S137-S143.
65. Jagust W., Thisted R., Devous M.D., Van Heertum R., Mayberg H., Jobst K., Smith A.D., Borys N. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001, 56:950-956.
66. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Foster N.L., Petersen R.C., Weiner M.W., Price J.C., Mathis C.A. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
67. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
68. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-{beta} dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
69. Kauwe J.S., Cruchaga C., Mayo K., Fenoglio C., Bertelsen S., Nowotny P., Galimberti D., Scarpini E., Morris J.C., Fagan A.M., Holtzman D.M., Goate A.M. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8050-8054.
70. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
71. Laakso M.P., Lehtovirta M., Partanen K., Riekkinen P.J., Soininen H. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol. Psychiatry 2000, 47:557-561.
72. Lee J.M., Blennow K., Andreasen N., Laterza O., Modur V., Olander J., Gao F., Ohlendorf M., Ladenson J.H. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 2008, 54:1617-1623.
73. Lerch J.P., Pruessner J.C., Zijdenbos A., Hampel H., Teipel S.J., Evans A.C. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb. Cortex 2005, 15:995-1001.
74. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
75. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., Kaye J.A., Raskind M.A., Zhang J., Peskind E.R., Montine T.J. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639.
76. Liddell B.J., Paul R.H., Arns M., Gordon N., Kukla M., Rowe D., Cooper N., Moyle J., Williams L.M. Rates of decline distinguish Alzheimer's disease and mild cognitive impairment relative to normal aging: integrating cognition and brain function. J. Integr. Neurosci. 2007, 6:141-174.
77. Lojkowska W., Ryglewicz D., Jedrzejczak T., Minc S., Jakubowska T., Jarosz H., Bochynska A. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci. 2003, 216:119-126.
78. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72:771-776.
79. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 2001, 32:367-381.
80. Maes O.C., Xu S., Yu B., Chertkow H.M., Wang E., Schipper H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging 2007, 28:1795-1809.
81. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 1999, 9:133-146.
82. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosen E., Aarsland D., Visser P.J., Schroder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttila T., Wallin A., Jonhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
83. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
84. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 1995, 36:1238-1248.
85. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
86. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.C., Roberts L.J., Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 1999, 155:863-868.
87. Montine T.J., Kaye J.A., Montine K.S., McFarland L., Morrow J.D., Quinn J.F. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch. Pathol. Lab. Med. 2001, 125:510-512.
88. Morris J.C., McKeel D.W., Storandt M., Rubin E.H., Price J.L., Grant E.A., Ball M.J., Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991, 41:469-478.
89. Olichney J.M., Morris S.K., Ochoa C., Salmon D.P., Thal L.J., Kutas M., Iragui V.J. Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2002, 73:377-384.
90. Pennanen C., Testa C., Laakso M.P., Hallikainen M., Helkala E.L., Hanninen T., Kivipelto M., Kononen M., Nissinen A., Tervo S., Vanhanen M., Vanninen R., Frisoni G.B., Soininen H. A voxel based morphometry study on mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 2005, 76:11-14.
91. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jagust W.J., Shaw L.M., Toga A.W., Trojanowski J.Q., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
92. Pogarell O., Teipel S.J., Juckel G., Gootjes L., Moller T., Burger K., Leinsinger G., Moller H.J., Hegerl U., Hampel H. EEG coherence reflects regional corpus callosum area in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:109-111.
93. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and " preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
94. Price J.L., Ko A.I., Wade M.J., Tsou S.K., McKeel D.W., Morris J.C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001, 58:1395-1402.
95. Price J.L., McKeel D.W., Morris J.C. Synaptic loss and pathological change in older adults - aging versus disease?. Neurobiol. Aging 2001, 22:351-352.
96. Prichep L.S., John E.R., Ferris S.H., Rausch L., Fang Z., Cancro R., Torossian C., Reisberg B. Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol. Aging 2006, 27:471-481.
97. Qin W., Ho L., Wang J., Peskind E., Pasinetti G.M. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One 2009, 4:e4183.
98. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
99. Raz N., Rodrigue K.M., Head D., Kennedy K.M., Acker J.D. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology 2004, 62:433-438.
100. Ridha B.H., Anderson V.M., Barnes J., Boyes R.G., Price S.L., Rossor M.N., Whitwell J.L., Jenkins L., Black R.S., Grundman M., Fox N.C. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J. Neurol. 2008, 255:567-574.
101. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch. Neurol. 2002, 59:1729-1734.
102. Risacher S.L., Saykin A.J., West J.D., Shen L., Firpi H.A., McDonald B.C. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr. Alzheimer Res. 2009, 6:347-361.
103. Rossini P.M., Del Percio C., Pasqualetti P., Cassetta E., Binetti G., Dal Forno G., Ferreri F., Frisoni G., Chiovenda P., Miniussi C., Parisi L., Tombini M., Vecchio F., Babiloni C. Conversion from mild cognitive impairment to Alzheimer's disease is predicted by sources and coherence of brain electroencephalography rhythms. Neuroscience 2006, 143:793-803.
104. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
105. Saez-Valero J., Fodero L.R., Sjogren M., Andreasen N., Amici S., Gallai V., Vanderstichele H., Vanmechelen E., Parnetti L., Blennow K., Small D.H. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J. Neurosci. Res. 2003, 72:520-526.
106. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
107. Sheline Y.I., Raichle M.E., Snyder A.Z., Morris J.C., Head D., Wang S., Mintun M.A. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 2010, 67:584-587.
108. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Hirai S. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998, 158:134-140.
109. Silverman W., Wisniewski H.M., Bobinski M., Wegiel J. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:377-379. discussion 389-392.
110. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., Phelps M.E. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
111. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging 2010, 31:758-764.
112. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
113. Snider B.J., Fagan A.M., Roe C., Shah A.R., Grant E.A., Xiong C., Morris J.C., Holtzman D.M. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol. 2009, 66:638-645.
114. Sperling R., Johnson K., Pontecorvo M., Safirstein B., Farmer M., Holub R., Korn R., Spicer K., Doraiswamy M., Reiman E., et al. PET imaging of β-amyloid with florpiramine F18 (18F-AV-45): preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease. Alzheimer's Dement. 2009, 5:197.
115. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
116. Stefani A., Martorana A., Bernardini S., Panella M., Mercati F., Orlacchio A., Pierantozzi M. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J. Neurol. Sci. 2006, 251:124-128.
117. Stoub T.R., Bulgakova M., Leurgans S., Bennett D.A., Fleischman D., Turner D.A., deToledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005, 64:1520-1524.
118. Sunderland T., Wolozin B., Galasko D., Levy J., Dukoff R., Bahro M., Lasser R., Motter R., Lehtimaki T., Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry 1999, 46:750-755.
119. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
120. Takahashi M., Stanton E., Moreno J.I., Jackowski G. Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias. Clin. Chem. 2002, 48:375-378.
121. Teipel S.J., Alexander G.E., Schapiro M.B., Moller H.J., Rapoport S.I., Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain 2004, 127:811-824.
122. Teipel S.J., Born C., Ewers M., Bokde A.L., Reiser M.F., Moller H.J., Hampel H. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage 2007, 38:13-24.
123. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., Galasko D., Pratico D., Griffin S., Schenk D., Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:6-15.
124. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci. Lett. 1999, 269:52-54.
125. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006, 5:655-660.
126. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293.
127. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009, 73:294-301.
128. Verbeek M.M., Kremer B.P., Rikkert M.O., Van Domburg P.H., Skehan M.E., Greenberg S.M. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann. Neurol. 2009, 66:245-249.
129. Wallin A., Blennow K., Rosengren L.E. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996, 7:267-272.
130. Welge V., Fiege O., Lewczuk P., Mollenhauer B., Esselmann H., Klafki H.W., Wolf S., Trenkwalder C., Otto M., Kornhuber J., Wiltfang J., Bibl M. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J. Neural. Transm. 2009, 116:203-212.
131. Wolk D.A., Price J.C., Saxton J.A., Snitz B.E., James J.A., Lopez O.L., Aizenstein H.J., Cohen A.D., Weissfeld L.A., Mathis C.A., Klunk W.E., De-Kosky S.T. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 2009, 65:557-568.
132. Yamaguchi H., Hirai S., Morimatsu M., Shoji M., Ihara Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol. 1988, 76:541-549.
133. Zarow C., Vinters H.V., Ellis W.G., Weiner M.W., Mungas D., White L., Chui H.C. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann. Neurol. 2005, 57:896-903.
134. Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., He P., McAllister C., Hampel H., Shen Y. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 2007, 64:718-726.